TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the first patient in Cohort 4 of its ...

XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

Gyre Therapeutics (GYRE) announced the publication of the manuscript titled “Hydronidone for the Treatment of Liver Fibrosis Associated with ...

Clinical symptoms and signs are a bridge between biomedicine and traditional medicine [TM]. These can be associated with diseases incl. their diagnosis, pharmacological targets, and the use of ...

On track for multiple clinical updates through mid-2026, including further progress from two ongoing clinical programs and initiation of ...

Routine use of urodynamic testing for overactive bladder (OAB) did not improve patient-reported outcomes when combined with ...

Avant Technologies Inc. (OTCQB:AVAI) (”Avant” or the “Company”), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease ...

Imunon has announced the alignment of the FDA with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

Introduction Eating disorders (EDs) are complex psychological and physiological disorders that often co-occur in the presence of other mental health difficulties. Mentalisation-based therapy (MBT) ...

Discover Skye Bioscience's progress on nimacimab with early trial enrollment, extended treatment protocols, and robust regulatory plans.

The primary value of placebo controls in clinical trials is the minimization of bias.